| Bioactivity | EACC is a reversible autophagy inhibitor, which can block autophagic flux. EACC selectively inhibits the translocation of autophagosome-specific SNARE Stx17 thereby blocking autophagosome-lysosome fusion[1]. | ||||||||||||
| Target | Autophagy | ||||||||||||
| Invitro | EACC blocks autophagosome-lysosome fusion but does not affect endo-lysosomal function[1].EACC inhibits autophagy by preventing SNARE Stx17 loading on autophagosomes[1].EACC does not affect RABs, tethers, and lysosomal SNARE but prevents their interaction with LC3 and Stx17[1]. | ||||||||||||
| Name | EACC | ||||||||||||
| CAS | 864941-31-1 | ||||||||||||
| Formula | C13H11N3O6S2 | ||||||||||||
| Molar Mass | 369.37 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Vats S, et al. A reversible autophagy inhibitor blocks autophagosome-lysosome fusion by preventing Stx17 loading onto autophagosomes. Mol Biol Cell. 2019 Aug 1;30(17):2283-2295. |